By
Blue Arbor Technologies, a medical technology company focused on neuromuscular interfaces and advanced prosthetic control systems, has announced a strategic partnership with global prosthetics leader Ottobock, anchored by a $5 million investment to accelerate development of Blue Arbor’s RESTORE™ Neuromuscular Interface System.
Under the agreement, Ottobock — a global MedTech pioneer with more than a century of innovation in prosthetics, neuro-orthotics, and wearable bionics — will serve as the lead investor in Blue Arbor’s Series A financing, take a seat on the company’s Board of Directors, and support the next stages of clinical validation, product development, and commercial readiness for the RESTORE™ platform.
The RESTORE™ System is a fully implanted neuromuscular interface designed to directly connect advanced prosthetic limbs to a patient’s residual muscles and peripheral nerves. By capturing and processing voluntary muscle and nerve signals, the system enables simultaneous, intuitive control of multiple joints — including fingers, wrist, and elbow — offering functional movement that closely resembles natural limb motion. Early human feasibility procedures, including the first-in-human implant at the Medical University of Vienna, have demonstrated rapid functional use with advanced prosthetic devices.
“This partnership and investment reflect a shared commitment to driving forward the next technological leap in prosthetic control,” said Ottobock CEO Oliver Jakobi. Ottobock’s involvement underscores confidence in the RESTORE™ platform’s potential to transform prosthetic function and enhance patient mobility and independence.
Blue Arbor’s leadership emphasizes that the RESTORE™ System is about designing technology that adapts to human biology — enabling prosthetic control that feels intuitive rather than requiring users to adapt to the device. This direct bio-integrated approach aims to overcome limitations of conventional control methods and other interfaces still in development.
The strategic partnership also builds on momentum from the project’s FDA Breakthrough Device Designation and inclusion in the FDA’s Total Product Life Cycle Advisory Program, milestones that support accelerated clinical study and regulatory pathways.
By combining Blue Arbor’s neuromuscular interface innovation with Ottobock’s global experience and resources, the collaboration seeks to bring transformative prosthetic control technology closer to widespread clinical use — offering new hope for people living with limb loss who seek more natural, reliable, and responsive prosthetic function.
